PFA

Revenue DeclineEbitda Margin CompressionNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹0.91

prior close

₹0.91

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-1.8% vs market

Pharmaceuticals & Biotechnology peers, median of 151sector · industry level+0.1%-1.2% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.2 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-2.2

15m

-1.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.7-1.8+0.1-1.2

Next day

-1.1+1.2-2.3+0.5-1.6

-3.3+1.2-4.5+0.7-4.0

-3.3+1.5-4.8+0.5-3.8

-2.2+1.8-4.0+1.0-3.2

-3.3+2.1-5.4+0.8-4.1

-3.3+1.9-5.2+0.2-3.5

15d

-4.4+3.6-8.0+1.4-5.8

-5.5+1.3-6.8-2.9-2.6

-9.9+6.6-16.5+1.3-11.2

-13.2+2.6-15.8-0.6-12.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals & Biotechnology peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shree Ganesh Biotech (India) Ltd announced audited results for FY25 (year ended March 31, 2025). Total revenue from operations grew to Rs 2,295.76 lakhs from Rs 2,027.77 lakhs in FY24, an increase of about 13%. However, net profit after tax fell sharply to Rs 27.84 lakhs from Rs 62.07 lakhs, a drop of roughly 55%, as expenses climbed faster than revenue. The fourth quarter (Q4 FY25) was particularly weak, posting a net loss of Rs 94.60 lakhs versus a profit of Rs 77.17 lakhs in the preceding quarter (Q3 FY25) and Rs 54.35 lakhs in Q4 FY24. Operating cash flow was negative at Rs (1,021.21) lakhs. The statutory auditor issued an unmodified (clean) opinion on the results.

Likely market impact

Mixed picture for shareholders — revenue is growing but profitability has compressed sharply and the latest quarter slipped into a loss, with negative operating cash flow signaling stress in core business operations. Near-term sentiment on the stock is likely to be cautious despite the clean audit report.